About Oxygenta Pharmaceutical Limited
Data last updated: 13 July 2026
Oxygenta Pharmaceutical Limited is a public limited company based in Medak, Telangana, India. It specialises in organic chemicals and compounds, a part of the broader chemicals and materials sector. Incorporated on 27 November 1990, the company has been in operation for over 36 years.
Registered with ROC Hyderabad under CIN L24110TG1990PLC012038. Listed on BSE: 524636.
Capital: an authorised share capital of ₹37.5 Cr and a paid-up capital of ₹36.98 Cr. Formerly known as S.S. Organics Pvt Ltd and S.S. Organics Ltd. It is led by directors including Vedavathi Gangavaram and Veera Reddy Arava.
Last AGM: 19 September 2025. Financial statements filed for year ended 31 March 2025. Office: Survey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India.
As per BSE-filed standalone financials for FY 2026, the company reported a revenue of ₹112.98 Cr, a growth of 3.37% compared to the previous year. Total assets are valued at ₹119.68 Cr (up 44.53% YoY).
The company has a workforce of approximately 98 employees as per the latest available data.
The company is associated with 2 brands - Oxygenta Pharmaceutical Ltd, S S Organics. As per MCA filings, the company has open charges of ₹46.6 Cr and satisfied charges of ₹55.7 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website oxygentapharma.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressSurvey No.252/1 Aroor Village Sadasivapet Mandal Medak District, Telangana, India
-
IndustryChemicals and Materials, Organic Chemicals & Compounds
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has undergone 2 name changes throughout its history. The company was previously known as S.S. Organics Pvt Ltd, and S.S. Organics Ltd.. The current legal name is Oxygenta Pharmaceutical Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Oxygenta Pharmaceutical Limited | Current |
| S.S. Organics Pvt Ltd | Previous |
| S.S. Organics Ltd. | Previous |
CIN History of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has one previous CIN (Corporate Identification Number): L24110AP1990PLC012038. The current CIN is L24110TG1990PLC012038, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1990PLC012038 | Current |
| L24110AP1990PLC012038 | Previous |
Associated Brands with Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited operates two associated brands: Oxygenta Pharmaceutical Ltd and S S ORGANICS. These brands represent Oxygenta Pharmaceutical Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Finished products and APIs are manufactured for therapeutic categories. | ssorganics.co.in | |
| Manufacturing of drugs, pharmaceutical preparations, and organic fine chemicals in India. | oxygentapharma.com |
Competitors & Alternatives of Oxygenta Pharmaceutical Limited
Brands and companies operating in the same space as Oxygenta Pharmaceutical Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Locked | Manufacturing | Locked | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Detailed business activity records for Oxygenta Pharmaceutical Limited
Activity codes and turnover contribution percentages require an active report plan.
- Activity group codes
- Detailed activity codes
- Turnover contribution
Verified entity values are shown only after access is granted.
Auditor Details of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is audited by M/s. A.M. Reddy & D.R. Reddy (ICAI peer reviewed, certificate valid till 2027-02-28) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s. A.M. Reddy & D.R. Reddy (ICAI peer reviewed, certificate valid till 2027-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is currently managed by 8 directors, with 41 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Oxygenta Pharmaceutical Limited FY 2026 filings available
Oxygenta Pharmaceutical Limited reported revenue of ₹112.98 Cr (up 3.37% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹112.98 Cr | ₹109.3 Cr | ₹39.64 Cr | ₹30.99 Cr | ₹60.52 Cr | ₹52.03 Cr | ₹13.72 Cr | ₹20.51 Cr |
| Other Income | ₹28.58 Lakh | ₹1.31 Cr | ₹4.24 Lakh | ₹1.78 Lakh | ₹45,000 | ₹9.12 Lakh | ₹3.36 Lakh | ₹1.3 Lakh |
| Total Income | ₹113.27 Cr | ₹110.61 Cr | ₹39.68 Cr | ₹31.01 Cr | ₹60.53 Cr | ₹52.12 Cr | ₹13.75 Cr | ₹20.52 Cr |
| Cost of Materials Consumed | ₹110.34 Cr | ₹100.23 Cr | ₹35.06 Cr | ₹28.13 Cr | ₹42.67 Cr | ₹43.02 Cr | ₹14.99 Cr | ₹17.75 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹8.2 Cr | -₹3.76 Cr | -₹1.53 Cr | -₹4.63 Cr | ₹4.55 Cr | -₹6.39 Cr | ₹58.88 Lakh | -₹1.67 Cr |
| Employee Benefit Expense | ₹7.64 Cr | ₹6.9 Cr | ₹5.99 Cr | ₹1.12 Cr | ₹33.04 Lakh | ₹73.28 Lakh | ₹60.45 Lakh | ₹80.22 Lakh |
| Finance Costs | ₹4.78 Cr | ₹3.61 Cr | ₹1.59 Cr | ₹1.49 Cr | ₹92.49 Lakh | ₹1.78 Cr | ₹1.09 Cr | ₹74.6 Lakh |
| Depreciation & Amortisation | ₹2.32 Cr | ₹1.78 Cr | ₹2.66 Cr | ₹2.05 Cr | ₹1.59 Cr | ₹1.2 Cr | ₹99.85 Lakh | ₹1.02 Cr |
| Other Expenses | ₹18.57 Cr | ₹15.92 Cr | ₹9.82 Cr | ₹13.49 Cr | ₹11.5 Cr | ₹10.82 Cr | ₹5.4 Cr | ₹5.67 Cr |
| Total Expenses | ₹135.45 Cr | ₹124.69 Cr | ₹53.59 Cr | ₹41.64 Cr | ₹61.57 Cr | ₹51.16 Cr | ₹23.68 Cr | ₹24.31 Cr |
| Profit Before Exceptional Items & Tax | -₹22.18 Cr | -₹14.08 Cr | -₹13.91 Cr | -₹10.64 Cr | -₹1.04 Cr | ₹95.51 Lakh | -₹9.93 Cr | -₹3.79 Cr |
| Exceptional Items | ₹0 | -₹27 Lakh | ₹3.7 Lakh | -₹73.44 Lakh | ₹54.64 Lakh | ₹2.19 Cr | ₹3.99 Cr | ₹30.1 Lakh |
| Profit Before Tax | -₹22.18 Cr | -₹14.35 Cr | -₹13.87 Cr | -₹11.37 Cr | -₹48.94 Lakh | ₹3.14 Cr | -₹5.94 Cr | -₹3.49 Cr |
| Total Tax Expense | -₹4.61 Cr | -₹4.05 Cr | -₹10.39 Cr | ₹19.83 Lakh | ₹12.11 Lakh | ₹21.39 Lakh | -₹15.32 Lakh | -₹23.9 Lakh |
| Net Profit | -₹17.57 Cr | -₹10.3 Cr | -₹3.48 Cr | -₹11.57 Cr | -₹61.05 Lakh | ₹2.93 Cr | -₹5.79 Cr | -₹3.25 Cr |
| Other Comprehensive Income | ₹52.54 Lakh | -₹10.73 Lakh | ₹7.11 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹17.05 Cr | -₹10.41 Cr | -₹3.41 Cr | -₹11.57 Cr | -₹61.05 Lakh | ₹2.93 Cr | -₹5.79 Cr | -₹3.25 Cr |
| EBITDA (computed) | -₹15.08 Cr | -₹8.69 Cr | -₹9.65 Cr | -₹7.1 Cr | ₹1.48 Cr | ₹3.93 Cr | -₹7.83 Cr | -₹2.03 Cr |
| Basic EPS | ₹-4.75 | ₹-2.86 | ₹-1.09 | ₹-6.36 | ₹-0.48 | ₹2.87 | ₹-5.67 | ₹-3.19 |
| Diluted EPS | ₹-4.75 | ₹-2.86 | ₹-1.04 | ₹-6.36 | ₹-0.48 | ₹2.87 | ₹-5.67 | ₹-3.19 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹119.68 Cr | ₹82.8 Cr | ₹63.19 Cr | ₹54.26 Cr | ₹31.18 Cr | ₹34.02 Cr | ₹18.62 Cr | ₹21.16 Cr |
| Non-current Assets | ₹68.25 Cr | ₹51.86 Cr | ₹39.09 Cr | ₹29.26 Cr | ₹21.91 Cr | ₹17.92 Cr | ₹11.85 Cr | ₹12.35 Cr |
| Current Assets | ₹51.43 Cr | ₹30.94 Cr | ₹24.11 Cr | ₹25.01 Cr | ₹9.16 Cr | ₹16.1 Cr | ₹6.77 Cr | ₹8.8 Cr |
| Property, Plant & Equipment | ₹47.6 Cr | ₹36.83 Cr | ₹29.36 Cr | ₹27.91 Cr | ₹19.98 Cr | ₹16.31 Cr | ₹11.42 Cr | ₹11.9 Cr |
| Inventories | ₹29.42 Cr | ₹20.51 Cr | ₹13.72 Cr | ₹11.71 Cr | ₹7.28 Cr | ₹12.11 Cr | ₹4.25 Cr | ₹5.33 Cr |
| Trade Receivables | ₹10.03 Cr | ₹5.1 Cr | ₹7.36 Cr | ₹10.16 Cr | ₹1.27 Cr | ₹1.61 Cr | ₹42.37 Lakh | ₹51.49 Lakh |
| Cash & Equivalents | ₹41.9 Lakh | ₹17,000 | ₹17,000 | ₹1.75 Lakh | ₹15.57 Lakh | ₹44.5 Lakh | ₹11.83 Lakh | ₹1.86 Lakh |
| Equity (Net Worth) | -₹42.69 Cr | -₹25.64 Cr | -₹20.12 Cr | -₹46.2 Cr | -₹34.63 Cr | -₹38.02 Cr | -₹40.95 Cr | -₹35.16 Cr |
| Equity Share Capital | ₹36.98 Cr | ₹36.98 Cr | ₹33.48 Cr | ₹14.2 Cr | ₹14.2 Cr | ₹10.2 Cr | ₹10.2 Cr | ₹10.2 Cr |
| Borrowings (Non-current) | ₹75.29 Cr | ₹21.52 Cr | ₹49 Cr | ₹63.02 Cr | ₹51.04 Cr | ₹45.04 Cr | ₹25.44 Cr | ₹20.87 Cr |
| Borrowings (Current) | ₹34.28 Cr | ₹40.71 Cr | ₹8.23 Cr | ₹4.97 Cr | ₹1.09 Cr | ₹2.85 Cr | ₹49.64 Lakh | ₹48.82 Lakh |
| Total Debt (computed) | ₹109.57 Cr | ₹62.23 Cr | ₹57.23 Cr | ₹67.99 Cr | ₹52.13 Cr | ₹47.89 Cr | ₹25.94 Cr | ₹21.36 Cr |
| Current Liabilities | ₹86.1 Cr | ₹85.85 Cr | ₹33.7 Cr | ₹26.04 Cr | ₹6.79 Cr | ₹19.01 Cr | ₹15.85 Cr | ₹16.73 Cr |
| Total Liabilities | ₹162.37 Cr | ₹108.44 Cr | ₹83.31 Cr | ₹100.46 Cr | ₹65.81 Cr | ₹72.04 Cr | ₹59.57 Cr | ₹56.32 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹27.75 Cr | ₹2.6 Cr | -₹13.05 Cr | -₹5.41 Cr | -₹2.93 Cr |
| Investing Cash Flow | -₹14.39 Cr | -₹11.25 Cr | -₹4.09 Cr | -₹9.64 Cr | -₹4.94 Cr |
| Financing Cash Flow | ₹42.56 Cr | ₹8.67 Cr | ₹17.13 Cr | ₹15 Cr | ₹7.58 Cr |
| Capital Expenditure | ₹12.86 Cr | ₹11.39 Cr | ₹4.11 Cr | ₹9.64 Cr | ₹4.95 Cr |
| Free Cash Flow (computed) | -₹40.61 Cr | -₹8.79 Cr | -₹17.16 Cr | -₹15.05 Cr | -₹7.87 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹41.73 Lakh | ₹2.09 Lakh | -₹54,000 | -₹4.94 Lakh | -₹28.93 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹49.61 Cr | ₹33.93 Cr | ₹14.3 Cr | ₹15.13 Cr | ₹49.47 Cr | ₹33.21 Cr | ₹14.01 Cr | ₹12.62 Cr |
| Other Income | ₹17.29 Lakh | ₹0 | -₹5.62 Lakh | ₹16.91 Lakh | ₹4.91 Lakh | ₹48.82 Lakh | ₹74.93 Lakh | ₹2.25 Lakh |
| Total Income | ₹49.79 Cr | ₹33.93 Cr | ₹14.25 Cr | ₹15.3 Cr | ₹49.52 Cr | ₹33.69 Cr | ₹14.75 Cr | ₹12.64 Cr |
| Cost of Materials Consumed | ₹46.54 Cr | ₹31.17 Cr | ₹16.97 Cr | ₹15.66 Cr | ₹44.03 Cr | ₹37.61 Cr | ₹7.94 Cr | ₹10.66 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹3.34 Cr | ₹36.98 Lakh | -₹4.53 Cr | -₹70.34 Lakh | -₹24.34 Lakh | -₹5.76 Cr | ₹2.9 Cr | -₹65.9 Lakh |
| Employee Benefit Expense | ₹1.72 Cr | ₹1.89 Cr | ₹2.03 Cr | ₹2 Cr | ₹2.19 Cr | ₹1.83 Cr | ₹1.4 Cr | ₹1.48 Cr |
| Finance Costs | ₹1.81 Cr | ₹1.39 Cr | ₹94.96 Lakh | ₹62.84 Lakh | ₹2.13 Cr | ₹38.83 Lakh | ₹69.09 Lakh | ₹40.68 Lakh |
| Depreciation & Amortisation | -₹24.11 Lakh | ₹85.92 Lakh | ₹85.71 Lakh | ₹84.73 Lakh | -₹23.37 Lakh | ₹70.6 Lakh | ₹65.99 Lakh | ₹64.94 Lakh |
| Other Expenses | ₹4.58 Cr | ₹4.58 Cr | ₹4.41 Cr | ₹5.01 Cr | ₹5.17 Cr | ₹3.88 Cr | ₹3.94 Cr | ₹2.92 Cr |
| Total Expenses | ₹51.07 Cr | ₹40.26 Cr | ₹20.68 Cr | ₹23.44 Cr | ₹53.04 Cr | ₹38.66 Cr | ₹17.53 Cr | ₹15.46 Cr |
| Profit Before Exceptional Items & Tax | -₹1.28 Cr | -₹6.33 Cr | -₹6.44 Cr | -₹8.14 Cr | -₹3.53 Cr | -₹4.96 Cr | -₹2.77 Cr | -₹2.82 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | -₹1.18 Lakh | -₹27 Lakh | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.28 Cr | -₹6.33 Cr | -₹6.44 Cr | -₹8.15 Cr | -₹3.8 Cr | -₹4.96 Cr | -₹2.77 Cr | -₹2.82 Cr |
| Total Tax Expense | ₹42.42 Lakh | -₹1.48 Cr | -₹1.51 Cr | -₹2.04 Cr | -₹1.65 Cr | -₹1.03 Cr | ₹8.05 Lakh | -₹1.45 Cr |
| Net Profit | -₹1.7 Cr | -₹4.84 Cr | -₹4.93 Cr | -₹6.11 Cr | -₹2.15 Cr | -₹3.93 Cr | -₹2.85 Cr | -₹1.36 Cr |
| Other Comprehensive Income | ₹52.54 Lakh | ₹0 | ₹0 | ₹0 | -₹10.73 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.18 Cr | -₹4.84 Cr | -₹4.93 Cr | -₹6.11 Cr | -₹2.26 Cr | -₹3.93 Cr | -₹2.85 Cr | -₹1.36 Cr |
| EBITDA (computed) | ₹28.72 Lakh | -₹4.08 Cr | -₹4.63 Cr | -₹6.66 Cr | -₹1.63 Cr | -₹3.87 Cr | -₹1.42 Cr | -₹1.76 Cr |
| Basic EPS | ₹-0.45 | ₹-1.32 | ₹-1.33 | ₹-1.65 | ₹-0.60 | ₹1.07 | ₹-0.81 | ₹0.39 |
| Diluted EPS | ₹-0.45 | ₹-1.32 | ₹-1.33 | ₹-1.65 | ₹-0.60 | ₹1.12 | ₹-0.78 | ₹0.37 |
Shareholding Pattern of Oxygenta Pharmaceutical Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 56.54%, domestic institutional investors hold 0.03%, retail and other public shareholders hold 43.44% of Oxygenta Pharmaceutical Limited. The company had 10,205 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 56.54% | 55.93% | 57.95% | 57.95% | 51.12% | 51.12% |
| Public | 43.46% | 44.07% | 42.05% | 42.05% | 48.88% | 48.88% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 56.54% | 51.12% | 29.73% |
| Public | 43.46% | 48.88% | 70.27% |
| Promoter change (YoY, %pts) | +5.42 | +21.39 | - |
Charges & Borrowings of Oxygenta Pharmaceutical Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2025 | Others | ₹46.6 Cr | Open |
| 02 Sep 2022 | Others | ₹5 Cr | Satisfied |
| 02 Sep 2022 | Others | ₹10 Cr | Satisfied |
| 21 Dec 2020 | Others | ₹6.7 Cr | Satisfied |
| 10 Sep 2020 | Others | ₹31.5 Cr | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited has a workforce of 98 employees as of Sep 11, 2024.
Employee and EPFO history for Oxygenta Pharmaceutical Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Oxygenta Pharmaceutical Limited
GST registrations and filing compliance for Oxygenta Pharmaceutical Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Oxygenta Pharmaceutical Limited
Credit ratings, litigation, and regulatory alerts for Oxygenta Pharmaceutical Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Oxygenta Pharmaceutical Limited
MSME payment history for Oxygenta Pharmaceutical Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Oxygenta Pharmaceutical Limited
Corporate group structure for Oxygenta Pharmaceutical Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Oxygenta Pharmaceutical Limited
MCA filings and documents for Oxygenta Pharmaceutical Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Oxygenta Pharmaceutical Limited
Frequently Asked Questions about Oxygenta Pharmaceutical Limited
Oxygenta Pharmaceutical Limited is an active public limited company in the chemicals and materials sector based in Medak, Telangana, India. It was incorporated on 27 November 1990 (36+ years old) and is registered under CIN L24110TG1990PLC012038. Listed on BSE: 524636. The company has 98 employees.
Oxygenta Pharmaceutical Limited reported revenue of ₹112.98 Cr for FY 2026 (up 3.37% YoY) based on standalone BSE filings.
The current directors of Oxygenta Pharmaceutical Limited are:
- Vedavathi Gangavaram - Director
- Veera Reddy Arava - Director
- Sidda Reddy Kanuparthi - Director
- Sharvari Swapnil Shinde - Director
- Chandra Mouliswar Reddy Gangavaram - Whole-Time Director
- Balasubba Reddy Mamilla - Whole-Time Director
- Janardhana Reddy Yeddula - Additional Director
- Amireddy Venkatesu Reddy - Additional Director
The primary industry of Oxygenta Pharmaceutical Limited is chemicals and materials. The company specifically operates in organic chemicals and compounds. The company is currently active in this sector.
Yes. Oxygenta Pharmaceutical Limited is listed on BSE with code 524636.
Oxygenta Pharmaceutical Limited can be reached at the registered office: Survey No.2521 Aroor Village Sadasivapet Mandal Medak District, Telangana, India, or through the website oxygentapharma.com.